Pfizer, Impax switch co-promotion duties to Lyrica

Share this article:
Impax Pharmaceuticals and Pfizer rejiggered their co-promotion agreement on Pristiq by swapping it out for Lyrica. Impax sales forces worked on Pristiq beginning in July 2009 after signing a three-year agreement with Wyeth, now part of Pfizer. Impax reps will now promote Lyrica.

Mark Donohue, a spokesperson at Impax, said the trade-off wasn't related to Pristiq sales figures, but had “more to do with our focus on high-prescribing neurologists.”

Impax's 66 sales reps commenced Lyrica promotion on April 1, and detailing is focused specifically on the drug's use as an adjunctive therapy for adult patients with partial onset seizures. Impax will no longer promote Pristiq.
Lyrica is also indicated for fibromyalgia, as well as nerve pain associated with diabetes and shingles.

As a result, Pfizer deployed it's own sales forces to neurologists, pain management specialists, endocrinologists and primary care physicians when the drug launched in 2005.

Pfizer nearly doubled its e-detailing spend in 2009, putting exponentially more dollars behind veteran brands like Aricept, Celebrex and the antibiotic Zyvox. However, Lyrica's e-detailing spend dropped 48% to $2.8 million through the first 11 months of 2009.

Total sales for Lyrica in 2009 were $267 million, up 10% from 2008, according to Pfizer's 2009 annual report. Pristiq sales figures for 2009 were conspicuously absent from the report. Pfizer webcast its annual meeting of shareholders on April 22.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...